Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1938 1
1942 1
1999 1
2005 1
2006 1
2007 2
2009 1
2010 1
2014 4
2015 15
2016 10
2017 12
2018 12
2019 15
2020 14
2021 6
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 30987772

87 results

Results by year

Filters applied: . Clear all
Page 1
Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
Gaillard SL, Andreano KJ, Gay LM, Steiner M, Jorgensen MS, Davidson BA, Havrilesky LJ, Alvarez Secord A, Valea FA, Colon-Otero G, Zajchowski DA, Chang CY, McDonnell DP, Berchuck A, Elvin JA. Gaillard SL, et al. Gynecol Oncol. 2019 Jul;154(1):199-206. doi: 10.1016/j.ygyno.2019.04.010. Epub 2019 Apr 13. Gynecol Oncol. 2019. PMID: 30987772
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, Trinh XB, Huizing MT, Tjalma W. Najim O, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31647985 Review.
Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A, Honisch E, Reinhardt F, Meier-Stiegen F, Yang L, Jaschinski S, Esposito I, Alberter B, Polzer B, Huebner H, Fasching PA, Pancholi S, Martin LA, Ruckhaeberle E, Schochter F, Tzschaschel M, Hartkopf AD, Mueller V, Niederacher D, Fehm T, Neubauer H. Franken A, et al. J Mol Diagn. 2020 Jan;22(1):111-121. doi: 10.1016/j.jmoldx.2019.09.004. Epub 2019 Oct 24. J Mol Diagn. 2020. PMID: 31669227 Free article.
ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, Cesarkas K, Farage-Barhom S, Saar EG, Eyal E, Kol N, Pavlovski A, Balint-Lahat N, Dick-Necula D, Barshack I, Kaufman B, Gal-Yam EN. Zundelevich A, et al. Breast Cancer Res. 2020 Feb 3;22(1):16. doi: 10.1186/s13058-020-1246-5. Breast Cancer Res. 2020. PMID: 32014063 Free PMC article.
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC. Schiavon G, et al. Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551. Sci Transl Med. 2015. PMID: 26560360 Free PMC article.
87 results